Latest Expert Opinions

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
October 23, 2020
They have made a very big impression through their cash-app. It gives users the ability to transact smaller amounts. No one wants to touch cash during COVID which has helped them do well. The POS side of the business has not done as well, but the stock has still done well. A great deal of the benefit of the future is already priced in. Many of the fintech stocks are a little over-valued.
Show full opinionHide full opinion
Square Inc (SQ-N)
October 23, 2020
They have made a very big impression through their cash-app. It gives users the ability to transact smaller amounts. No one wants to touch cash during COVID which has helped them do well. The POS side of the business has not done as well, but the stock has still done well. A great deal of the benefit of the future is already priced in. Many of the fintech stocks are a little over-valued.
BUY
BUY
October 23, 2020

This stock should skate through a change in administration or even another Trump term. Americans are quite happy with private healthcare solutions. 180M Americans have some sort of private health. 75% are happy with this so it would probably not be disrupted in a large way. He prefers Anthem but there is no problem with UNH.

Show full opinionHide full opinion

This stock should skate through a change in administration or even another Trump term. Americans are quite happy with private healthcare solutions. 180M Americans have some sort of private health. 75% are happy with this so it would probably not be disrupted in a large way. He prefers Anthem but there is no problem with UNH.

DON'T BUY
DON'T BUY
October 23, 2020

It is a value trap and Intel has been a serial disappointer. The report from last night stated their data centre business continues to deteriorate. They are getting beaten by their competitor, notably AMD. Stay clear of Intel.

Show full opinionHide full opinion
Intel (INTC-Q)
October 23, 2020

It is a value trap and Intel has been a serial disappointer. The report from last night stated their data centre business continues to deteriorate. They are getting beaten by their competitor, notably AMD. Stay clear of Intel.

DON'T BUY
DON'T BUY
October 23, 2020

One of the companies going through a vaccine trial. They were in the news recently because they had to pause trials due to an illness in a test participant. However, it is not just about the vaccine. They have consumer, pharma and medical device. There is still litigation list from the talc issue. It trades at 15x earnings, which is reasonable but it does take into account vulnerabilities. He prefers BDX.

Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
October 23, 2020

One of the companies going through a vaccine trial. They were in the news recently because they had to pause trials due to an illness in a test participant. However, it is not just about the vaccine. They have consumer, pharma and medical device. There is still litigation list from the talc issue. It trades at 15x earnings, which is reasonable but it does take into account vulnerabilities. He prefers BDX.

BUY
BUY
October 23, 2020
He likes CVS a lot fundamentally and also on a valuation basis. The company is vertically integrating. They most recently bought an insurer and also introduced a good partial solution to costly healthcare solutions. The HealthHub gives access to a nurse partitioner who can prescribe medical treatment. There is a long run-way in this regard. They trade at less than 10x earnings with a good dividend. There is some execution risk.
Show full opinionHide full opinion
CVS Health Corp (CVS-N)
October 23, 2020
He likes CVS a lot fundamentally and also on a valuation basis. The company is vertically integrating. They most recently bought an insurer and also introduced a good partial solution to costly healthcare solutions. The HealthHub gives access to a nurse partitioner who can prescribe medical treatment. There is a long run-way in this regard. They trade at less than 10x earnings with a good dividend. There is some execution risk.
COMMENT
COMMENT
October 23, 2020
A compelling stock with a good business plan. They have built their franchise well in North America and China. The valuation is very expensive and that has always stopped him. There are more compelling valuations.
Show full opinionHide full opinion
Starbucks (SBUX-Q)
October 23, 2020
A compelling stock with a good business plan. They have built their franchise well in North America and China. The valuation is very expensive and that has always stopped him. There are more compelling valuations.
BUY WEAKNESS
BUY WEAKNESS
October 23, 2020

They may not do well in the work-at-home space. This space demands more and more bandwidth and dispersion is greater. Cisco Webex is a competitor to Microsoft Teams. The average ticket for their product is very high and board members are reticent of spending. Once we see more clarity for after the pandemic, it will do well. He believes in the leadership team.

Show full opinionHide full opinion
Cisco (CSCO-Q)
October 23, 2020

They may not do well in the work-at-home space. This space demands more and more bandwidth and dispersion is greater. Cisco Webex is a competitor to Microsoft Teams. The average ticket for their product is very high and board members are reticent of spending. Once we see more clarity for after the pandemic, it will do well. He believes in the leadership team.